Erica Samp's COVID fight: From healthy to heart monitor



I spent an entire hour of my show on Thursday talking about Sen. Ron Johnson’s (R-Wis.) most recent COVID roundtable, a full four years after the scamdemic first began manically manipulating our health and our freedom. And I promise to never stop spending time on this issue because I think it is the most important work I’ve ever done in my life or will ever do.

COVID was a destroyer of worlds, and intentionally so. Nothing about it ever made sense except from a truly demonic perspective. I’ve talked to many of the same brave dissident experts that Johnson did, and the only conclusion one can reach from giving them a fair hearing is that somebody must pay for these crimes against humanity.

“I felt like I was going to die at any moment because my body was just attacking itself.”

There needs to be accountability for what they did to people like Iowa’s Erica Samp — one of the still countless people who emails me with their stories — so that it never happens again.

“I was perfectly healthy prior to getting the Moderna vaccinations,” wrote Samp, a 41-year-old mother of three.

I should have been informed of the risks. I should have had the opportunity to know that there were side effects beyond just a sore arm for a couple days. I should have been told that the concoction is not even a vaccine by definition, and it does not even work to prevent COVID! I should have been given the choice to decide if the risks outweigh the benefits for me! I should not have been able to be forced and mandated to get the vaccine by my employer. I should not have been forced to choose between getting extra money to get the shots and having to pay more if I did not. All of this coercion and bribery and force at the same time the risks and data were hidden from us. How is that legal? I had a perfect life before I was used as a human guinea pig. We are human beings. We are real. We are not just statistics and numbers that billion-dollar corporations can hide and pretend like we do not exist.

Unlike most who took the jab willingly as an almost religiously sacramental act of blind obedience to the Spirit of the Age, Samp wanted no part of it. In May 2021, however, she was backed into a difficult corner when her employer said, “Do it, or else.” Just like too many other corporate agents of tyranny at the time.

Her then-2-year-old son was suffering from a medical condition, which, without proper treatment covered by her health insurance, could have quickly become a life-or-death matter. Yet, even though her job had remote capability and most of her company had already worked off-site for a year, her request to continue to work from home to avoid the jab while keeping her insurance was denied.

Samp’s choice was either to play Russian roulette with her health or let her baby boy suffer. Most of us can see that’s not really a choice, just as more and more Americans can now see the poison poke was never “safe and effective.”

“I have lost vision in my right eye, partial hearing in both ears, my brain is swollen with lesions, I have to wear a heart monitor, and I lose feeling in my hands and feet,” Samp recently told me.

Even though she had some issues immediately after the first dose, Samp said she was not informed of any potential side effects besides a sore arm and possibly being tired for a day or two. Then came June 24 and her second shot, and there was simply no denying thereafter that the loving act of keeping her boy safe and healthy was trying to kill her.

“I felt like I was going to die at any moment because my body was just attacking itself,” said Samp, who was referred to visit the Mayo Clinic in February 2022. “I spent days up there being put through every test possible. I had to suffer through needles in my spine to collect tubes of spinal fluid that left me with headaches for weeks that were unbearable.”

She also had multiple IVs placed in both hands, and both of her eyes were dilated as strongly as possible so she could not see for more than 48 hours.

“They placed a catheter in my artery for angiograms. I spent well over six hours having to lay in an MRI machine for brain and spine imaging while being forced to wear a paper mask as well as a plastic mask. I could not move or I would have to start the test over again,” she said.

“It all felt like torture.”

And in the end, it was all for nothing. “They could not find any other cause for my injuries,” Samp told me.

Ain’t that some Wuhan luck for ya?

And clearly, after four years of this demonic garbage, that’s the only luck our overlords will allow us to have.

“Mistakes were made.” “We have to move on.” “But don’t forget to take that 10th booster!”

Did I mention that somebody must pay for this?

On that front, Samp has raised enough money to retain both a worker's compensation lawyer and a constitutional attorney. She plans to sue the federal government for willful misconduct in violation of the PREP Act, which otherwise provides immunity from liability for the government after responding to conditions determined to be a “present or credible risk of a future public health emergency.”

Is that Anthony Fauci I hear cackling, “I am the science!” in the background? Liability? What liability?

We aren’t seriously going to let Fauci and his assorted cast of Mengeles get away with this forever, are we? So let us pray for Samp and her cause. And in case you are wondering, imprecatory prayers will do just fine.

The Difference Between the Vaccine and a Cucumber | #Shorts

The Difference Between the Vaccine and a Cucumber | #Shorts

FDA advisory committee considers risk of heart inflammation from Moderna's COVID-19 vaccine



The U.S. Food and Drug Administration's vaccine advisory committee heard testimony Tuesday that Moderna's COVID-19 vaccine may carry a higher risk of heart inflammation in young men than the vaccine produced by Pfizer/BioNTech.

A panel of outside experts met Tuesday to consider whether the emergency use authorization for Moderna's mRNA vaccine should be expanded to include children ages 6 to 17 years old. The advisory committee will consider expert testimony from FDA scientists and then vote on whether Moderna's shot should be approved for children alongside Pfizer's COVID-19 vaccine.

Data presented to the committee by Dr. Tom Shimabukuro, a vaccine safety official at the U.S. Centers for Disease Control and Prevention, suggested that people ages 18 to 39 had a higher risk of myocarditis if they took the Moderna vaccine compared to those who had received the Pfizer shot.

But Shimabukuro cautioned that these findings were not consistent across U.S. databases, and he emphasized that heart inflammation remains a rare vaccine side effect.

According to the CDC, as of May 26, 2022, there have been 635 reports of myocarditis in children ages 5-17 who took the Pfizer vaccine. Putting that number in context, Shimabukuro said there have been nearly 55 million total Pfizer vaccine doses administered over the same period. Most of those that developed heart inflammation problems were adolescent boys who had received a second vaccine dose.

All children who reported having myocarditis recovered at least somewhat after it was diagnosed, and 80.1% of those diagnosed fully, or probably fully, recovered, according to a CDC survey of health care providers that treated them.

Comparing the Moderna vaccine to the Pfizer vaccine, Shimabukuro said there were slightly higher reporting rates of myocarditis for Moderna and that the reporting rate was higher in males.

Data from three U.S. vaccine safety databases showed the risk of myocarditis and pericarditis in young males aged 18-39 was 1.1 to 1.5 times higher after the Moderna shot, he said.

More CDC data on 18- to 39-year-olds showed 4.41 excess heart inflammation cases per 100,000 who took the Pfizer vaccine compared to 6.27 excess cases per 100,000 for Moderna. The Moderna vaccine is administered in higher doses than the Pfizer vaccine.

The FDA also reviewed Moderna's studies showing the efficacy of the vaccine in children 6 to 17. Officials said the vaccine was 93% effective among adolescents 12-17 and 77% effective in younger children. While these results met the agency's criteria for success, FDA officials warned that a booster shot will likely be needed for children, just like adults, because the vaccine's effectiveness wanes over time.

If the advisory committee votes to approve Moderna's vaccine for children, the question will go back to the FDA which must decide whether to take the committee's recommendation.

The committee will meet again Wednesday to consider whether the Pfizer and Moderna vaccines should be approved for use in infants under 5.

Moderna to test COVID-19 vaccine on infants as young as 6 months old



Biotechnology company Moderna Therapeutics will soon begin large-scale testing of its COVID-19 vaccine on infants.

The vaccine clinical trial, called KidCOVE, is being carried out at 79 locations across 13 states and will involve roughly 13,275 participants between the ages of 6 months and 11 years old in its entirety.

The first phase — which has already been completed — involved children between the ages of 6 years to less than 12 years old. The study is now reportedly in its second phase, during which children between the ages of 2 years to less than 6 years old will undergo testing. The third and final stage will test the vaccine on children ages 6 months to less than 2 years old.

In August, trial administrators reportedly amassed all the participants they needed for each stage.

Participants in the clinical trial are given two injections in the upper arm about 28 days apart and are then asked to return with their guardian to the study site for at least four follow-up appointments over the next 13 months, according to KidCOVE.

"The primary purpose of the KidCOVE Study is to test the safety and effectiveness of the study vaccine, called mRNA-1273, that may protect children between the ages of 6 months to < 12 years from getting sick if they come into contact with SARS-CoV-2, which causes COVID-19," KidCOVE's website states.

Just the News reported that the controversial study has only received sporadic media attention so far, citing local news coverage in Miami and Charlotte about participants. The outlet added that the testing is being undertaken despite the fact that most public health experts agree that the risk for children infected with COVID-19 is very low.

Vaccine administration in children has been a hot-button issue in America for several months. Those opposed to giving COVID-19 vaccines to children argue it is unnecessary due to the virus' negligible effect on them. But proponents, like Dr. Bill Hartman, the co-principal investigator of the clinical trial at the University of Wisconsin-Madison, say vaccine administration in children is "the final frontier" in the fight against the pathogen.

"Our very youngest children need to get the vaccine and we need to make sure they are safe," he said in a press release issued on Monday "The kids participating are heroes. They will be able to tell the story of how they helped save the world."

Moderna says third dose likely necessary this fall as antibody levels wane and impact vaccine's efficacy



Drugmaker Moderna says a third dose of its COVID-19 vaccine will "likely to be necessary this fall." The pharmaceutical and biotechnology company believes a booster shot will likely be necessary because the spread of the Delta variant and vaccine efficacy could be diminished since antibody levels were expected to wane.

"We believe that increased force of infection resulting from Delta, non-pharmaceutical intervention (NPI) fatigue, and seasonal effects (moving indoors) will lead to an increase of breakthrough infections in vaccinated individuals," Moderna said on Thursday. "While we see durable Phase 3 efficacy through 6 months, we expect neutralizing titers will continue to wane and eventually impact vaccine efficacy."

The vaccine maker noted, "Given this intersection, we believe dose 3 booster will likely be necessary prior to the winter season."

Moderna CEO Stéphane Bancel told Fox Business the company is "waiting for a bit more data," but the COVID-19 booster shot could be available "as soon as September" for elderly populations who received the COVID-19 vaccine in January and February.

"And so it's important that people who are vaccinated a long time ago, especially with vaccines that have had lower efficacy, be protected so they are not hospitalized this fall and winter," he told host Maria Bartiromo on Thursday.

On Wednesday, the World Health Organization implored wealthy nations to hold off on the coronavirus booster shots because of vaccine inequity.

"We need an urgent reversal from the majority of vaccines going to high-income countries, to the majority going to low income countries," WHO Director General Tedros Adhanom Ghebreyesus said at a press briefing.

Moderna claimed a study found its COVID-19 vaccine to be 93.2% effective against the coronavirus six months after the second dose, 98.2% effective against severe coronavirus maladies, and 100% effective in stopping death caused by COVID-19. The biotech company also boasted that its COVID-19 offers "effectiveness against variants of concern (VOCs), including Alpha, Beta/Gamma and Delta, even after partial vaccination."

"We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant," Bancel told CNBC on Thursday.

Moderna expects to manufacture between 800 million to 1 billion COVID-19 vaccine doses in 2021 worldwide, and forecasts to supply up to 3 billion doses in 2022.

The United States has administered over 348.1 million doses of COVID-19 vaccines as of Wednesday, Reuters reported. Broken down by manufacturer, there have been 195 million coronavirus vaccine doses from Pfizer-BioNTech administered, almost 140 million from Moderna, and more than 13 million from Johnson & Johnson, according to CDC data.

The COVID-19 vaccine announcements were made on Thursday during Moderna's second-quarter earnings presentation. Moderna boasted about second-quarter revenue of $4.4 billion, $4.2 billion of which came from COVID-19 vaccine sales, according to the financial announcement. Moderna said it had generated $4 billion of cash in the second quarter, and held a total of $12.2 billion in cash and investments.

Despite the notable financial news, Moderna shares fell 2.4% in the premarket.

Last month, Pfizer announced that it enjoyed second-quarter revenues of $7.8 billion, half of which came from its COVID-19 vaccine developed with Germany's BioNTech. Pfizer expects to generate $33.5 billion in COVID-19 sales in 2021.

During Thursday's presentation, Moderna also announced that it is working on mRNA-1010, a quadrivalent seasonal flu vaccine. The pharmaceutical company said the mRNA flu vaccine was entering Phase 2 trials, and is currently looking for trial participants in the U.S. and Puerto Rico.

Moderna is also working on mRNA-1345m, a vaccine for Respiratory syncytial virus (RSV), a "common respiratory virus that usually causes mild, cold-like symptoms," but can be "serious, especially for infants and older adults."

Health experts say 1 dose of Pfizer, Moderna COVID-19 vaccines are effective against coronavirus, encourage people to get second dose for 'maximum protection'



Health experts say that one dose of the Pfizer or Moderna COVID-19 vaccine is effective against the coronavirus, according to Yahoo!.

What are the details?

New research from the Centers for Disease Control and Prevention has determined that Pfizer and Moderna's mRNA vaccines for COVID-19 are "exceedingly effective at preventing the disease after just one dose."

A recent study analyzed data from at least 3,950 health professionals and essential and frontline workers who underwent weekly testing for the coronavirus for a duration of 13 weeks after they were vaccinated.

"[R]esearchers discovered that the vaccines were 80 percent effective at preventing COVID-19 after one dose, and 90 percent effective after two doses," the outlet noted.

In clinical trials, the Pfizer-BioNTech vaccine was 52% effective after just one dose, and 95% effective after two doses.

For Moderna's clinical trials, the vaccine was 50.8% effective up to two weeks after the original dose and 92.1% effective after that, with an efficacy of 94.1% after two doses.

What else?

Dr. William Schaffner, infectious diseases specialist and professor at the Vanderbilt University School of Medicine, said that he's "not entirely sure" why there has been such a large increase in how effective the COVID-19 vaccines are in preventing disease after just one dose.

"[T]his is data from continuing analysis of larger populations," he told the outlet, "and it's encouraging."

The encouraging data, according to Dr. Shobha Swaminathan — an association professor in the Division of Infectious Diseases at Rutgers University — "supports what many of us have felt."

"After two weeks, most vaccines will have some efficacy, and the degree of efficacy would relate to the potency of the vaccine," Swaminathan said.

Swaminathan added, "We do not know how durable the vaccine response will be for these products if people stop at one dose."

But experts say that it remains of utmost importance for people to receive two shots of a two-shot COVID-19 vaccine series.

"I do think we need that second dose in order to get maximum protection," Schaffner added, insisting that people get "much more antibodies" when they receive the second dose. "Please get the second dose. You need to get complete protection. We can't tell you that you're going to have 95 percent protection on the basis of a single dose, and you're likely to have longer protection this way."

Dr. Thomas Russo, professor and chief of infectious diseases at the University of Buffalo in New York, added, "I can't emphasize enough how important it is to get the second dose. ... Only a minority of people have severe, systemic symptoms. Even if you have flu-like symptoms, you take a 'vaccine day.' It's a small price to pay for getting a really tremendous degree of protection from this coronavirus."

CDC director: Data suggests vaccinated people don't carry COVID-19



Centers for Disease Control and Prevention Director Dr. Rochelle Walensky announced on Monday that scientific evidence suggests people vaccinated against COVID-19 almost never carry the virus.

Appearing for an interview with MSNBC host Rachel Maddow, Walensky said: "Our data from the CDC today suggests that vaccinated people do not carry the virus, don't get sick, and that it's not just in the clinical trials, but it's also in real-world data."

CDC Director Dr. Rochelle Walensky: “Our data from the CDC today suggest that vaccinated people do not carry the vi… https://t.co/SPrrZJJHkb
— The Recount (@The Recount)1617125532.0

On Monday the CDC released a study that found the Pfizer and Moderna vaccines were 90% effective after two doses and were 95% effective in preventing COVID-19. The study looked at nearly 4,000 front-line workers, some of whom were vaccinated and some not, who were tested weekly for COVID-19 between December and March.

Among those who had been vaccinated, only three individuals developed COVID-19 infections, while there were 161 positive COVID-19 cases among those who did not receive a vaccine.

"This is very reassuring news," study lead author Mark Thompson said. "We have a vaccine that's working very well."

On Wednesday, Sen. Rand Paul (R-Ky.) cited Walensky in a tweet that called on White House top health adviser Dr. Anthony Fauci to admit that vaccinated people are not at risk of spreading COVID-19.

"Please end the mask theater now that cdc admits evidence that vaccinated do not carry the virus," Paul said.

paging Dr Fauci:  please end the mask theater now that cdc admits evidence that the vaccinated do not carry the vir… https://t.co/9lXUQfvnOP
— Senator Rand Paul (@Senator Rand Paul)1617204381.0

Earlier this month, Paul and Fauci had a public disagreement over mask-wearing during a Senate hearing on the federal government's COVID-19 response.

Paul argued that there is no data to suggest a vaccinated individual is at risk of carrying or spreading COVID-19 and said that therefore, vaccinated Americans should not have to wear masks or observe social distancing guidelines.

Fauci "totally" disagreed with Paul, warning that new variants of COVID-19 put people at risk of reinfection, but he did not point to a scientific study that shows there is significant risk of that happening.

Paul accused Fauci of "making policy based on conjecture."

Last week, researchers launched a National Institute of Health-backed study to determine if there is significant risk of asymptomatic spread of COVID-19 among people who have received Moderna's vaccine. The study will examine 12,000 college students from 21 different college campuses who volunteer to participate. Half of the volunteers will receive Moderna's vaccine at the onset of the study, while the other half will receive their shots in four months. Researchers will regularly test the students for COVID-19 to see if the vaccine protects against asymptomatic spread.

"We hope that within the next five or so months we'll be able to answer the very important question about whether vaccinated people get infected asymptomatically, and if they do, do they transmit the infection to others," Fauci said during a White House COVID-19 task force briefing on Friday.

In the meantime, the federal government is likely to recommend that people vaccinated for the virus continue to wear masks.

Boston doctor experiences 'severe' reaction just minutes after receiving Moderna vaccine



A Boston physician experienced a "severe" reaction just minutes after being inoculated with Moderna's vaccine on Christmas Eve.

The New York Times reported that the reaction was the first of its kind to be linked to the Moderna vaccine, which was rolled out across the United States last week.

What are the details?

Dr. Hossein Sadrzadeh, a geriatric oncologist at Boston Medical Center, had a severe anaphylactic reaction immediately after receiving the Moderna shot. Dr. Sadrzadeh told the Times the allergic reaction was the same as those he experiences with shellfish.

More from the Times:

He said that within minutes of the vaccine injection at 3:30 p.m., his heart rate had spiked to 150 beats per minute, about twice its normal cadence; his tongue prickled and went numb. Before long, he was drenched in a cold sweat and found himself feeling dizzy and faint. His blood pressure also plummeted, he said. His immune system, he realized, was in revolt.

"It was the same anaphylactic reaction that I experience with shellfish," Dr. Sadrzadeh said. Dr. Sadrzadeh used his EpiPen and was taken on a stretcher to the emergency room, where he was given several medications, including steroids and Benadryl, to calm the immune reactions that had overtaken his body. A record of his visit stated that he had been "seen in the ER for shortness of breath, dizziness, palpitations and numbness after receiving the Covid-19 vaccine."

"He was taken to the Emergency Department, evaluated, treated, observed and discharged. He is doing well today," David Kibbe, a spokesman for Boston Medical Center, said in a statement.

What is causing the reactions?

There have been numerous allergic reactions to coronavirus vaccines. The Food and Drug Administration said the week before Christmas that officials were investigating reactions that happened in several states with the Pfizer vaccine, which was rolled out one week prior to the Moderna vaccine.

Although experts still aren't certain what triggered the reactions, officials say the vaccines are safe.

Still, the Centers for Disease Control and Prevention issued updated guidance on the vaccine for Americans with a history of severe allergic reactions.

"If you have ever had a severe allergic reaction to any ingredient in a COVID-19 vaccine, CDC recommends that you should not get that specific vaccine. If you have had a severe allergic reaction to other vaccines or injectable therapies, you should ask your doctor if you should get a COVID-19 vaccine. Your doctor will help you decide if it is safe for you to get vaccinated," the new guidance read.

Meanwhile, Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, has identified polyethylene glycol as the potential "culprit" behind the reactions.

The ingredient is present in both Pfizer's vaccine and Moderna's vaccine.

As of Sunday, more than 9.5 million doses of COVID-19 vaccine had been distributed across the U.S., and nearly 2 million Americans had been inoculated, according to CDC data.

Country star Dolly Parton donated $1 million to help fund Moderna's COVID-19 vaccine research



Legendary country music star Dolly Parton was a major early funder of a potentially effective coronavirus vaccine, Rolling Stone reported Tuesday.

What are the details?

In April, Parton announced on social media that she donated $1 million to the Vanderbilt University Medical Center in Nashville, Tennessee, for coronavirus research. Now, several months later, it has been revealed that her donation went toward funding Moderna's COVID-19 vaccine, the second vaccine in recent days to report a surprisingly high success rate against the virus in human trials.

"My longtime friend Dr. Naji Abumrad, who's been involved in research at Vanderbilt for many years, informed me that they were making some exciting advancements toward research of the coronavirus for a cure," Parton wrote on Instagram at the time regarding her decision to donate. "I am making a $1 million donation to Vanderbilt towards that research and to encourage people that can afford it to make donations. Keep the faith."

Speaking with NBC News Tuesday morning after hearing the news about Moderna's vaccine, Parton indicated she was happy to hear that her donation made a difference.

"When I donated the money to the COVID fund I just wanted it to do good and evidently, it is! Let's just hope we can find a cure real soon," she said.

When I donated the money to the Covid fund I just wanted it to do good and evidently, it is! Let’s just hope we can… https://t.co/Mn4KoAUEuw
— Dolly Parton (@Dolly Parton)1605631620.0

What else?

On Monday, Moderna announced that its vaccine, developed under President Trump's Operation Warp Speed, turned out a 94.5% success rate in preventing the virus during large-scale human trials.

According to a CNBC report, "The analysis evaluated 95 confirmed COVID-19 infections among the trial's 30,000 participants."

"Moderna, which developed its vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, said 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the group that received its two-dose vaccine. That resulted in an estimated vaccine efficacy of 94.5%," the report added.

The news of its success rate followed similar findings from Pfizer's vaccine trials, which announced Nov. 9 that its vaccine has shown to be 90% effective against the virus.

Both companies have heralded the results and promised to produce tens of millions of doses of the vaccines for deployment in the United States by the end of 2020 and potentially more than 1 billion doses globally by the end of 2021.

The reports marked major breakthroughs in the fight against the novel coronavirus that has plagued the world for the last year after first being discovered in Wuhan, China. In all, the virus has infected over 50 million people globally, killing more than 1 million.